Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zai Lab Ltd ( (HK:9688) ) has shared an update.
Zai Lab Limited announced its unaudited interim results for the six months ending June 30, 2025, showing a 15% increase in net product revenue to $214.7 million, driven by higher sales of key products. The company also reported a decrease in net loss by 33% to $89.2 million, attributed to revenue growth outpacing operating expenses, alongside reduced research and development, and administrative costs due to resource prioritization and efficiency efforts.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$27.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company based in the Cayman Islands, focusing on developing and commercializing innovative therapies. The company is known for its products like VYVGART, NUZYRA, and XACDURO, which are aimed at increasing market penetration and coverage.
YTD Price Performance: 28.23%
Average Trading Volume: 16,527,120
Technical Sentiment Signal: Buy
Current Market Cap: HK$29.89B
For a thorough assessment of 9688 stock, go to TipRanks’ Stock Analysis page.